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Abstract
Introduction: While adjuvant immunotherapy with Bacille Calmette Guérin (BCG) is effective in non-muscle-invasive 
bladder cancer (BC), adverse events (AEs) are considerable. Monocyte-derived activated killer cells (MAK) are discussed 
as essential in antitumoural immunoresponse, but their application may imply risks. The present trial compared 
autologous intravesical macrophage cell therapy (BEXIDEM®) to BCG in patients after transurethral resection (TURB) of 
BC.
Materials and methods: This open-label trial included 137 eligible patients with TaG1-3, T1G1-2 plurifocal or unifocal 
tumours and ≥ 2 occurrences within 24 months and was conducted from June 2004 to March 2007. Median follow-up 
for patients without recurrence was 12 months. Patients were randomized to BCG or mononuclear cells collected by 
apheresis after ex vivo cell processing and activation (BEXIDEM). Either arm treatment consisted of 6 weekly instillations 
and 2 cycles of 3 weekly instillations at months 3 and 6. Toxicity profile (primary endpoint) and prophylactic effects 
(secondary endpoint) were assessed.
Results: Patient characteristics were evenly distributed. Of 73 treated with BCG and 64 with BEXIDEM, 85% vs. 45% 
experienced AEs and 26% vs. 14% serious AEs (SAE), respectively (p < 0.001). Recurrence occurred significantly less 
frequent with BCG than with BEXIDEM (12% vs. 38%; p < 0.001).
Discussion: This initial report of autologous intravesical macrophage cell therapy in BC demonstrates BEXIDEM 
treatment to be safe. Recurrence rates were significantly lower with BCG however. As the efficacy of BEXIDEM remains 
uncertain, further data, e.g. marker lesions studies, are warranted.
Trial registration: The trial has been registered in the ISRCTN registry http://isrctn.org under the registration number 
ISRCTN35881130.
Introduction
TURB is the therapeutic gold standard for non-muscle
invasive BC. Up to 50-70% of cases recur, rendering BC
one of the most prevalent malignancies [1]. According to
the respective guidelines the use of adjuvant therapy is
warranted in patients with intermediate to high risk for
tumour recurrence and progression, i.e. multifocal and
recurrent disease [1,2]. Two basic forms of adjuvant treat-
ment have been established to date: chemotherapy and
BCG. Chemotherapy is antimetabolic and its use recom-
mended in intermediate risk patients [2]. In contrast,
BCG stimulates immunoresponse [3]. The use of BCG is
suitable for patients with intermediate and high-risk dis-
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ease and its superiority over chemotherapy has been
demonstrated [1,4-6].
While the efficacy of BCG is generally regarded as ade-
quate, its use is debated in low and intermediate risk
patients, as its limiting factor is toxicity [1,7,8]. Adverse
events (AE) are related to its mode of action, as BCG
stimulates immunoreaction and local and systemic
inflammatory response occurs. The most frequent immu-
notherapy linked AEs include constellations of flu- and
cystitis-like symptoms. Systemic toxicities, i.e. fever,
occur in up to 20% of patients. Due to AEs a considerable
portion of patients has been reported to discontinue BCG
and many urologists reduce applications [9].
BCG is the most efficacious adjuvant therapy for BC
and acts via complex and diverse mechanisms. It is stimu-
lating T-cell mediated local immunoresponse via various
cytokines [10,11]. It thus triggers granulocyte related
antitumour action [12-15], and macrophage cytotoxicity
[11]. BCG has a significant effect on macrophage mobility
and phagocytosis. Tumour-infiltrating dendritic cells and
tumour associated macrophages counter BCG- effects
[16,17]. Natural killer cells and macrophages are viewed
as important targets in the cascade of immunoresponse
[18,19].
The rationale to apply activated monocytes into the
bladder has been studied with regard to the mode of
action of BCG [20-22]. Macrophages may be obtained in
l a r g e  q u a n t i t i e s  b y  c u l t u r e  o f  b l o o d  m o n o c y t e s .  A f t e r
activation with interferon-gamma (IFN-γ) ex vivo, mac-
rophages are capable of selectively lysing tumour cells.
The antitumoural properties of IFNγ-activated mac-
rophages have been demonstrated in vitro in experimen-
tal murine models of human tumours [23]. Monocyte-
derived activated killer (MAK) cells are autologous,
highly purified, IFNγ-activated macrophages obtained
through in vitro culture. Tolerance and preliminary activ-
ity of intrapleural infusion of MAK cells have been
assessed in mesothelioma [24] and residual peritoneal
ovary carcinomas [25].
A prior phase I trial of autologous MAK cells (BEXI-
DEM®) in patients with non-muscle invasive bladder can-
cer was conducted. Intravesical BEXIDEM therapy was
administered after TURB to 17 patients with TaG3 or
recurrent TaG2 BC [26]. MAK cells were obtained from
autologous mononuclear cells harvested by apheresis and
processed by ex vivo culture for 7 days and activated with
IFN-γ on the last day of culture. The patients received 6
weekly intravesical instillations of approximately 2 × 108
cells each. Each patient was followed for 1 year or until
tumour recurrence, whichever came first. A total of 112
intravesical instillations were performed. No patients dis-
continued treatment due to an AE and no grade 3 serious
AE (SAE) was reported. In 17 patients, 8 tumour recur-
rences were observed during the 12 months following the
first BEXIDEM instillation compared to 34 occurrences
despite various adjuvant therapies including BCG in the
same patients during the 12 months before (p ≤ 0.0005).
Immunoresponse after BEXIDEM was reflected in
increased urinary interleukin-8 (IL-8), granulocyte-mac-
rophage colony-stimulating factor (GM CSF), IL-18,
elastase and neopterin indicating neutrophil and mac-
rophages activation, respectively [19].
No previous larger data on the use of MAKs exist. The
application of viable MAK may trigger various immuno-
logical reactions and imply essential systemic risks elu-
sive to smaller series. Thus following the phase I trial, a
subsequent larger phase II trial was designed to gather
further data on BEXIDEM therapy in patients with non-
muscle invasive papillary bladder cancer after TURB.
While the secondary objective was to evaluate overall
efficacy and recurrence rates in patients treated with
BEXIDEM compared to BCG, the primary objective was
to demonstrate a superior safety profile of BEXIDEM
over BCG.
Materials and methods
This open-label, randomized study was conducted in 43
centres in Spain, Hungary, France, Germany, Belgium and
Luxembourg in accordance with the Declaration of Hel-
sinki, the International Conference on Harmonisation
guideline for Good Clinical Practice and local laws
between June 2004 and March 2007. The study was spon-
sored by IDM Pharma, Inc. Ethical oversight was pro-
vided by institutional or regional Ethics Committees and
signed informed consent was received from each patient.
Prior to randomization, patients underwent complete
TURB of all suspect lesions. Histopathological examina-
tion was conducted according to the 1973 WHO classifi-
cation and the TNM staging system [27,28]. Patients with
plurifocal tumours and patients with a unifocal tumour
having a history of at least two occurrences within the
prior 24 months were included in the study. Patients were
excluded if BC exceeded T1G2, in case of carcinoma in
situ, history of tuberculosis, other malignancies within 5
years, active infection and systemic reaction to BCG. Pre-
vious BCG treatment was not an exclusion criterion.
P a t i e n t s  w e r e  r a n d o m i z e d  t o  B E X I D E M ®  or BCG. To
minimize prognostic imbalance, patients were stratified
according to 3 predefined risk groups (A, B, and C) [29]
(table 1). In multiple tumours, the highest grade deter-
mined overall tumour grade.
The sample size calculation assumed that 10% and 30%
of BEXIDEM and BCG patients, respectively, would
experience at least 2 AEs or 1 AE resulting in withdrawal.
A sample size of 138 (69 per arm) would provide 80%Burger et al. Journal of Translational Medicine 2010, 8:54
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power to demonstrate this difference with a 2-sided sig-
nificance level of 0.05.
The BEXIDEM dose and regimen used in the study
were based on prior phase I experience [26]. Patients ran-
domized to BEXIDEM had mononuclear cells and plasma
collected by apheresis of peripheral blood and shipped to
an IDM laboratory in Paris, France. There, monocytes
were processed by ex vivo culture in the presence of
recombinant human GM-CSF and autologous serum to
promote their differentiation to macrophages, which
were subsequently activated with IFN-γ. The resulting
doses of MAK were cryopreserved, formulated and
shipped to the patient's investigational center. Each dose
was provided as a frozen sterile, aqueous, suspension of
MAK cells containing 10% dimethylsulfoxide (DMSO)
and 5% human serum albumin (HSA) in 50 mL cryobags.
Each cryobag contained 2 × 108 MAK cells in a volume of
10 mL. This formulation was kept frozen until use and
diluted with HSA prior to administration by bladder
instillation (figure 1).
BCG was supplied in packages containing one vial of
the freeze-dried product containing 1 to 19.2 × 108 CFUs.
BCG dose and regimen were consistent with the usual
adult dose as recommended in the approved product
labelling (ImmuCyst, Sanofi Pasteur Limited, Paris,
France). Cystoscopy was performed immediately before
the first instillation of each treatment cycle to exclude
vesical tumour. The first treatment cycle was initiated
within 3 to 6 weeks after TURB and consisted of 6 weekly
instillations of BEXIDEM or BCG. Maintenance con-
sisted of 2 cycles (at month 3 and month 6) of 3 weekly
BEXIDEM or BCG instillations.
Dose reductions of BEXIDEM due to toxicity were not
allowed. Dose reductions of BCG to 2/3 or 1/3 of the rec-
ommended dose due to toxicity were allowed and had to
be documented. Delays in treatment with either BEXI-
DEM or BCG to allow for resolution of toxicity were
allowed.
AEs were assessed prior to every instillation and at 9
weeks, 9 and 12 months after the initial application. Fol-
low-up cystoscopy was performed at 3, 6, 9 and 12
months. The primary safety endpoint was based on the
incidence of AEs according to the Common Terminology
Criteria for AEs (CTCAE). The relationship of an AE to
study treatment was determined by the investigator. AEs
were coded using the Medical Dictionary for Regulatory
Activities (MedDRA), version 9. Efficacy was evaluated as
RFS. All visible lesions detected during follow-up were
biopsied and recurrent BC confirmed by histopathology.
Progression was defined as recurring BC invading mus-
cle.
Fisher's exact test was used to compare the treatment
groups with respect to the proportion of patients who
experienced 2 or more treatment related AEs or 1 treat-
ment related AE that resulted in study withdrawal; the
distribution of low, normal, and high values for labora-
tory parameters; and the distribution of normal and
abnormal results on physical examination. A 2-sample t-
test was used to compare the treatment groups with
respect to laboratory values and vital signs at each visit.
Fisher's exact test was used to compare the treatment
groups with respect to the proportion of patients who
experienced tumour recurrence. Figure 1 Scheme of BEXIDEM preparation and administration.
Table 1: Stratification according to risk for recurrence prior to randomization according to predefined groups and 
distribution of BEXIDEM and BCG among the risk groups.
Group TNM Classification Number of Tumors BEXIDEM® BCG
A Ta Grade 1
T1 Grade 1
Single or multiple
Single
26 29
B Ta Grade 2
T1 Grade 1
T1 Grade 2
Single or multiple
Multiple
Single
26 26
C Ta Grade 3
T1 Grade 2
Single or multiple
Multiple
23 23Burger et al. Journal of Translational Medicine 2010, 8:54
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Results
Out of 153 patients randomized, 6 withdrew consent, 2
experienced AEs before treatment, in 1 apheresis was
unsuccessful and in 7 protocol violation occurred prior to
treatment including other anti-cancer therapy. 137
patients were treated (64 with BEXIDEM, 73 with BCG).
All patient characteristics were evenly distributed
between the groups (table 2). Previous treatment was
most often reported as TURB (45% BEXIDEM, 59%
BCG) or TURB plus chemotherapy (23% BEXIDEM, 23%
BCG).
All patients tolerated apheresis and no AEs were
reported other than related to peripheral venipuncture.
Immunotherapy-related AEs were experienced by 45%
(29/64) and 85% (62/73) of BEXIDEM and BCG patients,
respectively. The number of patients with either (i) two or
more treatment related AEs, or (ii) one treatment related
AE resulting in study withdrawal was 31% (20/64) in
BEXIDEM and 78% (57/73) in BCG, respectively (p <
0.001). The most common treatment related AEs
reported for BEXIDEM patients were hematuria (14%, 9/
64), dysuria (13%, 8/64), and urinary tract infection (14%,
9/64), while the most common treatment related AEs
reported for BCG-treated patients were dysuria (41%, 30/
73), pyrexia (30%, 22/73), pollakisuria (25%, 18/73), and
urinary tract infection (38%, 28/73). Serious AEs were
experienced by 14% (9/64) of BEXIDEM and 26% (19/73)
of BCG treated patients, respectively. Treatment was dis-
continued due to treatment related AEs in 1 patient
treated with BEXIDEM (prostatitis) and 6 patients
treated with BCG (table 3). Treatment related AEs
reported for patients who discontinued in the BCG group
included systemic reaction to BCG with fever , dyspnea,
and urinary tract infection.
The median follow-up for patients without recurrence
was 11.9 months (BEXIDEM: 11.6, BCG: 12.2; range 0.1-
23.8). Recurrence (with or without progression) occurred
in 24/64 (38%) of BEXIDEM and 9/73 (12%) of BCG
patients, respectively. Thus recurrence was significantly
more frequent in the BEXIDEM arm (p < 0.001). In the
BEXIDEM group, 11 of these patients were in risk group
A, 11 were in group B, and 4 were in group C. In the BCG
group, 6 of these patients were in risk group A, 3 were in
group B, and 1 was in group C. Progression to muscle
invasive disease occurred in 2/64 (3%) and 1/73 (1%),
respectively. One patient in the BEXIDEM group died
without relation to treatment or disease.
Discussion
Non-muscle invasive BC recurs frequently. According to
a widely accepted model by Millan-Rodriguez and a more
recent model by Sylvester [29,30] patients included into
the present study were at intermediate risk for recurrence
requiring adjuvant therapy but at low risk for progression
according to respective guidelines [1]. BCG is most com-
monly used in patients at high risk for progression but is
also justified in patients at sufficient risk of recurrence as
patients included in the present trial. As the efficacy of
BEXIDEM could not be reliably judged, no patients at
high risk of progression, e.g. CIS, were included in order
to avoid undue risks.
While local immunotherapy with BCG is the most
effective agent in preventing recurrence, frequent AEs
(e.g., cystitis, mild fever) and less common but severe
complications (e.g., fever, granulomatous prostatitis)
occur [2-4]. The feasibility to develop novel adjuvant
agents in addition to chemotherapy or BCG is twofold;
for one it would be ideal to combine the efficacy of BCG
with a more advantageous AE profile and secondly thera-
peutic options are limited following failure of one sub-
stance [1].
As BCG is an immunotherapeutic and BC is viewed as
susceptible to respective targeting, it is feasible to pursue
further immunotherapeutical approaches. Autologous
MAK cell therapy has been reported as a promising treat-
ment modality including BC [24,17]. While BCG is medi-
ating activation of the immune system via T-cells and its
action is not tumour specific, MAK-cells are targeting
tumour cells. Their mode of action may be considerably
more specific resulting in an improved safety profile
[26,19]. However, safety is a concern in treating patients
with MAK, as these central agents of immunoresponse
could trigger widespread immunological reactions.
Hence safety was chosen as the primary endpoint for the
present trial and accordingly the protocol defined adverse
events in a strict manner, explaining the rather high over-
all rates of any AEs in both arms (BEXIDEM: 45%; BCG:
85%). Even taking the present and rather strict approach
in mind, BEXIDEM appeared safe.
Table 2: Demographics
Parameter BEXIDEM
N = 75
BCG
N = 78
Age
Mean 63 62.8
Median 63 64.5
Range 43-83 27-83
Sex
Male 62 (83%) 64(82%)
Female 13 (17%) 14 (18%)
Ethnic Group
Caucasian 75 (100%) 77 (99%)
Mediterranean 0 (0%) 1 (1%)Burger et al. Journal of Translational Medicine 2010, 8:54
http://www.translational-medicine.com/content/8/1/54
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In comparison to BCG, the incidence of SAEs was sig-
nificantly lower in the BEXIDEM arm, as 14% versus 26%
of BEXIDEM and BCG patients experienced serious AEs,
and 1 and 6 patients discontinued the protocol due to
BEXIDEM and BCG related SAEs, respectively. The
safety profile demonstrated in the BCG group was consis-
tent with what would be expected with this approved
product and is described in the product labelling and lit-
erature [1].
While this phase II trial returned the results expected
based on the previous study [26] with respect to its pri-
mary objectives, a significantly higher proportion of
BEXIDEM versus BCG-treated patients experienced BC
recurrence. The agents applied were applied correctly, i.e.
BCG in accordance to the current EAU- guidelines and
BEXIDEM dosing and regimen in accordance to prior
phase I experience [1,26]. Viability of BEXIDEM was rou-
tinely assessed and no breech of protocol was noted in
processing, handling or administering the product ruling
out reduced activity by mishandling.
The efficacy of BEXIDEM is uncertain and three
aspects are noteworthy suggesting a careful interpreta-
tion of the results. For one, the rather low numbers and
events in the prior phase I trial may not reflect the true,
i.e. potentially low efficacy of BEXIDEM. Secondly, this
phase II trial was underpowered for the secondary clini-
cal end-point and the sample size calculation was apt to
reflect safety only in accordance to the primary endpoint.
Thirdly the overall numbers of recurrence events were
low which has to be attributed to the risk profile of most
patients, which in retrospect was inadequately advanta-
geous for assessing efficacy. Fourthly, even if a certain
prophylactic effect was present, it may have been over-
ruled by the close to optimal prophylactic effect of BCG.
Unfortunately no information on the frequency of previ-
ous tumour occurrences was obtained upon inclusion
into this trial.
Thus the efficacy of BEXIDEM remains uncertain.
Planning the present trial marker lesion studies were
extensively discussed but decided against due to concerns
that larger tumor burden is a known challenge for immu-
notherapeutic approaches, which rely on immune cell
numbers to overwhelm tumor cell numbers. Further tri-
als are warranted and should adopt the marker lesion
concept by observing rather small tumour. Future trials
should furthermore include assessment of efficacy by his-
topathological analysis of bladder tissue biopsies follow-
ing the application of BEXIDEM immunological panels.
Conclusions
In this initial randomized trial of autologous MAK cell
therapy for non-muscle-invasive BC, BEXIDEM demon-
strated an adequate safety profile compared to BCG and
no widespread immunological reactions were triggered.
Recurrences rates in BEXIDEM were significantly higher
compared to BCG. Marker lesions and immunological
panels are warranted to assess efficacy of this novel
immunotherapeutic agent.
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Table 3: Summary of Immunotherapy- related Adverse Events (Patients who received at least one dose of study drug)
Parameter BEXIDEM®
(N = 64)
BCG
(N = 73)
P
No. of patients with AE 29 (45.3%) 62 (84.9%) < 0.001
16 (25.0%) 39 (53.4%) < 0.001
Grade Moderate
Grade Severe 7 (10.9%) 12 (16.4%) 0.4593
Relationship Probable 7 (10.9%) 31 (42.5%) < 0.001
Relationship Definite 3 (4.7%) 26 (35.6%) < 0.001
No. of patients who discontinued due to an AE 1 (1.6%) 6 (8.2%) 0.121Burger et al. Journal of Translational Medicine 2010, 8:54
http://www.translational-medicine.com/content/8/1/54
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